Posted on

HAVN Life Enters Into Distribution Agreement With Mycrodose Therapeutics for U.S. Market

HAVN Life Enters Into Distribution Agreement With Mycrodose Therapeutics for U.S. Market

The Agreement allows HAVN Life to export naturally derived psilocybin from its Jamaica facility and grows roster of supply partners in the U.S. market

Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, is thrilled to announce its entry into an exclusive U.S. Distribution Agreement (the “Exclusive Distribution Agreement”) with California-based Mycrodose Therapeutics Inc. (“Mycrodose”), a leading pharmaceutical company in the U.S. specializing in the research and development of advanced drug delivery systems utilizing DEA Schedule I, II and III drugs and other compounds aimed at treating cancer related conditions, mental health, and cognitive degenerative diseases.

HAVN Life and Mycrodose have entered into the Exclusive Distribution Agreement to facilitate the import of HAVN Life’s naturally derived GMP psilocybin into the United States for authorized research purposes. The Exclusive Distribution Agreement allows HAVN Life & Mycrodose to provide naturally derived GMP psilocybin to research institutions/researchers within the U.S. at competitive prices, which should assist with alleviating the supply chain issues currently facing researchers who are unable to find GMP psilocybin at an affordable price.

“HAVN Life is kicking off 2022 with strong partnerships in both our research and retail divisions, and we are very excited to start fulfilling purchase orders for our research customers with our new U.S. distribution partner, Mycrodose Therapeutics,” says HAVN Life CEO, Tim Moore. “We’ve been working closely with Chad and his team, and are excited about the potential of this partnership.”

Mycrodose is one of only a handful of pharmaceutical companies that has been authorized by the United States Drug Enforcement Agency (“DEA”), State of California Attorney General’s Research Advisory Board, and The Food & Drug Administration (“FDA”) to import and research six (6) Schedule I, II and III compounds. In December 2021, Mycrodose added a Schedule I Import license which allows the import of Schedule I psilocybin and psilocin.
DEA import authorization gives Mycrodose the ability to import the controlled substance of psilocybin and psilocin for clinical trials, research and development, analytical purposes, and distribution to its clients for authorized research purposes.

“Our company’s proven ability to navigate the meticulous details required for approval by the DEA and FDA for these very difficult licenses has directly contributed to Mycrodose’s ability to lead the U.S.-Pharmaceutical sector working with these highly controlled-substances here in the United States,” says Chad Conner, Chief Executive Officer of Mycrodose Therapeutics. “This distribution partnership with HAVN Life increases access and the ease of obtaining GMP psilocybin for any U.S.-based research institution, university, or private biotech company working with this Schedule I compound. Mycrodose is dedicated to advancing research within this sector and this is one of many ways that we are helping,” he adds.

The interest and demand for psilocybin research in the United States has grown significantly in 2021 and continues to outpace supply in 2022. Recently the Drug Enforcement Agency (DEA) again increased the quota for psilocybin research in the U.S. HAVN and Mycrodose have already successfully completed a first purchase order and delivery of naturally derived GMP raw psilocybin mushrooms from Jamaica into the United States, and Mycrodose is actively handling new enquiries from approved DEA licensed institutions and research organizations.

HAVN Life’s operations in Jamaica are facilitated by strategic partnerships with Hypha Wellness and P.A. Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybe mushrooms.
For more information on obtaining naturally derived GMP psilocybin contact Mycrodose Therapeutics at www.MycrodoseThera.com

###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for investigational research in an effort to define the future of modern medicine. HAVN Life offers a full range of high-quality mushroom and plant extracts that help support immune function and support a healthy lifestyle.

Purchase our plant-based Natural Health Products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

About Mycrodose Therapeutics
Mycrodose Therapeutics Inc. is a U.S.-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing DEA Schedule I-III drugs and other compounds to treat cancer related conditions, mental health, and cognitive degenerative diseases. The company believes that its IP-Protected Sustained Microdosing Technology™ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.

Contact:

Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Exclusive Distribution Agreement, Mycrodose’s business, products and future of Mycrodose’s business and the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the anticipated benefits from the Exclusive Distribution Agreement will not be realized as contemplated, or at all, risks that Mycrodose’s products and plan will vary from those stated in this news release and Mycrodose may not be able to carry out its business plans as expected and risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.LinkedInFacebookTwitterEmailShare

Posted on

HAVN Life Successfully Exports Psilocybin From Jamaica Facility Into the U.S. For Research Purposes

HAVN Life Successfully Exports Psilocybin From Jamaica Facility Into the U.S. For Research Purposes

The Company was able to export naturally derived psilocybin to their California-based Supply Partner, Mycrodose Therapeutics late last week.

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential active pharmaceutical ingredients (APIs) to support brain health, is pleased to announce it has successfully exported naturally derived psilocybin from its facility in Jamaica into the U.S.

HAVN Life’s operations in Jamaica are facilitated by strategic partnerships with Hypha Wellness and P.A. Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybin-containing mushrooms for authorized research purposes.

The importation of the naturally derived psilocybin into California was completed after the Company’s supply partner Mycrodose Therapeutics was granted an import license from the United States Drug Enforcement Administration (DEA). Mycrodose will be acting as a distributor for HAVN Life’s naturally-derived psilocybin in the United States, allowing the Company to fulfill the various supply agreements it has in place.

“With their track-record of working with the U.S. Food and Drug Administration (“FDA”), a proven track record of core business fundamentals, and registration with the DEA, Mycrodose Therapeutics is an ideal supply partner for HAVN Life,” says CEO Tim Moore. “Having a supply partner that gives us access to the rapidly growing U.S. market for research purposes is absolutely key for us as we look to expand our business in 2022,” he adds.

The successful import by Mycrodose Therapeutics in the U.S. comes on the heels of HAVN Life’s recent announcement of the import of naturally derived psilocybin into Canada by their supply partner, Nectar Health Sciences Laboratory Division Inc., signalling a ramping up of supply chain activities and positioning HAVN Life as an early mover with its ability to supply companies with high-quality, naturally derived psilocybin for investigational research for potential therapeutic purposes.

“This partnership helps support our company’s ambitious product development and R&D milestones by offering a potential alternative to synthetic derived psilocybin at a fraction of the cost for use in investigational research,” says Mycrodose Therapeutics CEO Chad Conner. “Most importantly, our partnership with HAVN Life helps address supply chain issues with obtaining GMP psilocybin for our own research and the research of other US-based Institutions researching psychedelics for authorized purposes,” he adds.

An MOU between HAVN Life and Mycrodose Therapeutics was announced in September, kickstarting a supply and distribution partnership that is now fully operational. The partnership will allow HAVN Life to provide naturally derived GMP psilocybin in the U.S. for authorized research purposes at competitive prices, and aims to help ease supply chain issues currently facing hundreds of pharmaceutical companies, research institutions, and nonprofits across the United States of American that cannot find psilocybin for authorized research purposes at an affordable price.

The supply of psilocybin to Mycrodose therapeutics will be in compliance with all applicable rules and regulations of the U.S. Drug Enforcement Administration.

###

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.

HAVN Life Sciences is a Vancouver, British Columbia based biotechnology company pursuing standardized extraction of psychedelic compounds to investigate their potential use as active pharmaceutical ingredients (APIs) to support brain health, along with non-psychedelic mushroom extracts as natural health products.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for investigation use for potential therapeutic purposes. Additionally, HAVN Life offers a new line of high-quality non- psychedelic mushroom and plant nutritional supplements that help support healthy immune function and support a healthy lifestyle.*

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

* These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

About Mycrodose Therapeutics

Mycrodose Therapeutics is a US-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. Mycrodose is one of only a few private companies that has been granted a Schedule I License and been approved by the United States Drug Enforcement Administration (DEA), State of California Attorney General’s Research Advisory Board, and The US Food & Drug Administration (FDA) to research four (4) psychedelic compounds: psilocybin, LSD, MDMA, and DMT. The company believes that its IP-Protected Sustained Microdosing Technology™ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.

Contact:

Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the exportation and importation of psilocybin-containing mushrooms, compliance with [the rules and regulations of the U.S. Drug Enforcement Administration] (the “[DEA] Compliance”), investigational research of psychedelic compounds for potential therapeutic purposes, Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the continued exportation and importation of psilocybin-containing mushrooms may not be completed as contemplated, or at all, risks that the Company may not be able to obtain or maintain DEA Compliance as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Posted on

HAVN Life Successfully Exports Psilocybin From Its Jamaica Facility Into Canada

HAVN Life Successfully Exports Psilocybin From Its Jamaica Facility Into Canada

The Company Signs Supply Agreement with Nectar Health Sciences Laboratory Division Inc. to provide naturally derived psilocybin for research and development of therapeutic products

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”)a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is pleased to announce it has successfully exported naturally derived psilocybin from its facility in Jamaica.

The importation of the naturally derived psilocybin into Canada was completed after the Company entered into a supply agreement with Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. Based out of Victoria, British Columbia, Nectar Health Sciences Laboratory Division Inc. has a Controlled Substance Dealer’s License for the relevant psychedelic compounds issued by Health Canada. Under that license, Nectar was granted an import permit, pursuant to the provisions of the Controlled Drugs and Substances Act and the Food and Drugs Regulations.

The agreement with Nectar Health Sciences Laboratory Division Inc. paves the way for HAVN Life’s successful exportation of naturally derived psilocybin from Jamaica. Additionally, it validates the Company’s supply chain business model of providing psilocybin for clinical use and research, adding to previously announced supply partnerships this year with Mycrodose Therapeutics, Mycotopia Therapies, Cube Psytech, Allied Health, ATMA Journey Centers, Revive Therapeutics and HealthTech Connex.

“This partnership is a huge win for us as we look to secure additional supply agreements with Canadian companies, now that the integrity of our supply chain from Jamaica has been demonstrated,” says HAVN Life CEO, Tim Moore. “As the research and drug development work on psilocybin moves forward, HAVN Life continues to position itself as a supply chain leader, able to meet the demand for naturally derived psilocybin,” he adds.

“We are pleased to be one of HAVN Life Sciences preferred supply partners,” says Kevin Coft, CEO of Psilobrain Therapeutics Inc. “Our Nectar Health Sciences Laboratory Division has been at the forefront of synthetic psychedelic research, and our supply agreement with HAVN Life Sciences compliments and initiates our next stage of comprehensive testing, analytics, extraction, and product development from psychedelic mushrooms cultivated and processed under stringent quality control protocols,” he adds.

The agreement and supply of psilocybin to Nectar Health Sciences Laboratory Division Inc. will be in compliance with all applicable Health Canada regulations.

###

 On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About Psilobrain Therapeutics Inc.

Psilobrain Therapeutics Inc. is a Canadian biotech company that draws on the latest advances in psychedelic medicine to produce scientifically designed products to facilitate evidence-based healing and wellness. Backed by our 3 Health Canada licenses, we ensure the highest quality of standard by integrating and controlling all aspects of the supply chain from sourcing our naturally derived psilocybin for research-developed formulations through our licensed R&D laboratory.

Psilobrain is committed to our Drug Development Program, with 3 provisional patents and numerous preclinical studies in various stages of research and data collection. and is an active contributor in the pharmaceutical, nutraceutical and psychedelic wellness industries. In addition to drug development, Psilobrain has partnered with Psychedelic Wellness Clinics to support emerging psychedelic therapies by collaborating with Clinical Counsellors on psychedelic prescription research, product development & data collection.

Our Management and Advisory team are industry veterans in the pharmaceutical & consumer goods industries. Members of our team have held C-suite and other senior positions within companies such as Med BioGene, Aspreva Pharmaceuticals, Teva Pharmaceutical Industries, Mount Sinai, Social Creatures, Green Sky Labs, Jimmy Pattison Group, and the British Columbia Association of Clinical Counsellors. Psilobrain Therapeutics is committed to our research-based approach of developing new modalities for healing and is well-positioned to bring that wellness to the community.

About HAVN Life Sciences Inc.

HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter,  Instagram and Youtube.

Contact:

Investor Relations: ir@havnlife.com  604 687-7130
Media: savi@emergence-creative.com 647 896-8078

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the supplying agreement with Nectar Health Sciences Laboratory Division Inc. (the “Supply Agreement”), the exportation and importation of psilocybin-containing mushrooms, compliance with Health Canada regulations (the “Health Canada Compliance”), the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the anticipated benefits of the Supply Agreement will not be realized as contemplated, or at all, risks that the continued exportation and importation of psilocybin-containing mushrooms may not be completed as contemplated, or at all, risks that the Company may not be able to obtain or maintain Health Canada Compliance as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

Posted on

Mycotopia Therapies Announces Plan to Develop Psychedelic Sublingual Tablet to Help Treat Depression

Mycotopia Therapies Announces Plan to Develop Psychedelic Sublingual Tablet to Help Treat Depression

Mycotopia Therapies (TPIA) and Agile Pharmaceutical Solutions formed a joint venture to develop an oral psilocybin tablet for depression. The companies may work with HAVN Life Sciences (HAVN) in Jamaica for assistance with development and sourcing materials.

PDF of article

Posted on

Microdosing research expands worldwide!

Wake Network, Inc. Receives Certificate of Drug Registration for Microdose Formulation in Jamaica

Yesterday, Wake Network Inc received a Certificate of Drug Registration from the Jamaican Ministry of Health & Wellness for PSIL428, its microdose formulation made from natural psilocybin.

The certification allows the company to run clinical trials on anxiety and depression and makes PSIL429 available to clinics and academic institutions across the globe. Any country with a special access program can request to import the legal formulation for patient use.

In other microdosing news, MindBio Therapeutics, a subsidiary of Blackhawk Growth Corp. (BLR), is partnering with Trip Pharma’s LeichtMind clinic to launch microdosing clinical trials in Canada!

PDF of article 1

PDF of article 2

Posted on

Save your relationship with a trippy vacay

MycoMeditations’ Psilocybin-Assisted Wellness Retreat Expands to Serve the Exclusive Dynamic of Family and Friends

It’s time to book a flight to Jamaica.

MycoMeditations launched a new psilocybin retreat called the Companion Retreat for guests to bond with their partner, friend, sibling, or parent on a new level. During the week-long retreat, guests participate in 3 magic mushroom trips at a beachfront villa in Jamaica, where shrooms have never been illegal. The experience includes preparation and integration sessions to get the most out of each trip, as well as support from staff members as needed.

 

Posted on

Psychedelic therapy retreat aims to use psilocybin to treat traumatic brain injury (TBI) in veterans

Ground-breaking research to explore the potential for psilocybin to treat traumatic brain injury

This Fall, Heroic Hearts Project will begin psychedelic therapy retreats in the Netherlands and Jamaica to study the effect of psilocybin on veterans with traumatic brain injury (TBI). Many veterans sustain brain injuries during their service, which can lead to issues like anxiety, depression, and substance abuse. The retreats aim to study both the psychological and physiological impacts of psilocybin therapy.

PDF of article

Posted on

Psychedelic “smart shops” to open in Jamaica

Psychedelic Mushroom Shops Reach The Americas

Many psychedelic companies are being drawn to Jamaica, one of the only countries where it’s legal to cultivate, extract, and sell psilocybin mushrooms. Silo Wellness is partnering with Mushe Inc. to open the first “smart shop” in the Western hemisphere, a psychedelic mushroom retail outlet that will sell functional and psychedelic mushrooms in various forms to locals and tourists.

Psyence Group formally began operations in Jamaica under its wholly owned subsidiary, Psyence Jamaica Ltd., which will focus on psilocybin treatment for patients in palliative care. To take on the new market, Psyence Jamaica is in collaboration with LONACAS Inc., a Jamaican clinical research company, and MycoMeditations, a “psilocybin wellness destination experience” in Treasure Beach, Jamaica.

Wake Network Inc. received clearance to conduct a “first-of-its-kind” clinical trial at a Jamaican university, which will study the effect of microdosing on depression and anxiety.

PDF of article

PDF of article 2

PDF of article 3